How China's Patent Linkage System Will be Implemented

August 13, 2021 | BY

Susan Mok

Ting Wu of Haiwen & Partners raises some questions to highlight how China's newly implemented drug patent linkage system attempts to resolve drug patent disputes in the early stages, which will have a sweeping impact on market entry strategies for chemical drugs in China

Summary

  • The patent linkage system intends to resolve drug patent disputes between originators and generic drug applicants in the early stages
  • The Chinese drug patent linkage system does not apply to drug patents that are not recorded in the Chinese Orange Book
  • The regulatory approval stay only applies to a patent protection scope dispute claim under a Category 4 Statement

 

 

This premium content is reserved for
China Law & Practice Subscribers.

  • A database of over 3,000 essential documents including key PRC legislation translated into English
  • A choice of newsletters to alert you to changes affecting your business including sector specific updates
  • Premium access to the mobile optimized site for timely analysis that guides you through China's ever-changing business environment
For enterprise-wide or corporate enquiries, please contact our experienced Sales Professionals at +44 (0)203 868 7546 or [email protected]